Dogwood Therapeutics (DWTX) vs Edesa Biotech (EDSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Dogwood Therapeutics (DWTX) over the past year, gaining 34.6% versus a loss of 77.9%. Over five years, EDSA leads with a -93.3% price change compared with -98.8% for DWTX. Edesa Biotech is the larger company by market cap ($49.5 million vs $47.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DWTX | EDSA |
|---|---|---|
| Share price | $1.41 | $3.66 |
| Market cap | $47.93M | $49.45M |
| 1-day change | -1.40% | -5.79% |
| YTD return | -66.11% | +157.75% |
| 1-year return | -77.90% | +34.56% |
| 5-year return | -98.80% | -93.31% |
| P/E ratio (TTM) | 0.64 | — |
| EPS (TTM) | $2.20 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.04 | $20.32 |
| 52-week low | $1.28 | $0.72 |
| Distance from 52-week high | -79.98% | -81.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +892.91% | +346.17% |
| Average volume | 63.03K | 62.13K |
| Shares outstanding | 33.99M | 13.51M |
| Employees | 8 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed DWTX by 112.5 percentage points over the past year.
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Healthcare · Biotechnology · 8 employees
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Healthcare · Biotechnology · 17 employees
DWTX vs EDSA FAQ
Which is bigger, Dogwood Therapeutics or Edesa Biotech?
Edesa Biotech (EDSA) is larger, with a market capitalization of $49.45M compared with $47.93M for Dogwood Therapeutics (DWTX).
Which stock has performed better over the past year, DWTX or EDSA?
EDSA returned +34.56% over the past 12 months, compared with -77.90% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Are Dogwood Therapeutics and Edesa Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.